# EDGAR Filing Document

**Accession Number:** 0001448431
**File Stem:** 0001628280-25-044425
**Filing Date:** 2025-10
**Character Count:** 9843
**Document Hash:** 4245fc14fc0088ba57120f539a3b1a10
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-044425.hdr.sgml**: 20251007

**ACCESSION NUMBER**: 0001628280-25-044425

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250821

**FILED AS OF DATE**: 20251007

**DATE AS OF CHANGE**: 20251007

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** D'Silva Andrew J.
- **CENTRAL INDEX KEY:** 0002083717

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38543
- **FILM NUMBER:** 251378748

**MAIL ADDRESS:**
- **STREET 1:** 23122 VISTA RAMONA ROAD
- **CITY:** RAMONA
- **STATE:** CA
- **ZIP:** 92065
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OptimizeRx Corp
- **CENTRAL INDEX KEY:** 0001448431
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 261265381
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 260 CHARLES STREET
- **STREET 2:** SUITE 302
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 248-651-6558

**MAIL ADDRESS:**
- **STREET 1:** 260 CHARLES STREET
- **STREET 2:** SUITE 302
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

## Ex-24

![](powerofattorneyandydsilv001.jpg)

Page 1 of 1 Power of Attorney (Andy D'Silva) 081825.docx OptimizeRx Corporation 260 Charles Street Suite 302 Waltham, MA 02453 OPTIMIZERX CORPORATION POWER OF ATTORNEY Known by all these presents, that the undersigned hereby constitutes and appoints each of Marion Odence-Ford and Edward Stelmakh, individually, with the full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of OptimizeRx Corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities and Exchange Act of 1934 and the rules and regulations promulgated thereunder; 2. do and complete any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; 3. take any other action of type whatsoever in connection with the foregoing which, in the opinion of such attorney- in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact, individually, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that each such attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of August, 2025. _____________________________________ Signature _____________________________________ Print Name Docusign Envelope ID: 5D290E55-C0F6-4B31-A9F9-59C18460D3A0 Andy D'Silva

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>D'Silva Andrew J.<br><sub>(Last) (First) (Middle)</sub><br>C/O OPTIMIZERX CORPORATION<br>260 CHARLES STREET, SUITE 302<br><sub>(Street)</sub><br>WALTHAM, MA 02453<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>OptimizeRx Corp [ OPRX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-08-21 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Business Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 37097<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option | <sup>(2)</sup> | 2029-10-01 | Common Stock | 6993 | $7.20 | D |  |
| Stock Option | <sup>(3)</sup> | 2026-08-31 | Common Stock | 40000 | $67.31 | D |  |
| Stock Option | <sup>(4)</sup> | 2027-10-02 | Common Stock | 13018 | $15.04 | D |  |
| Stock Option | <sup>(5)</sup> | 2028-12-19 | Common Stock | 5892 | $12.73 | D |  |
| Stock Option | <sup>(6)</sup> | 2029-12-11 | Common Stock | 13723 | $4.95 | D |  |

---

### Footnotes:

(1) Includes 24,890 shares of common stock underlying unvested restricted stock units ("RSUs") granted under OPRX's equity incentive plans. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of OPRX common stock. The RSUs vest as follows: (i) 8,000 RSUs which represent the 4th and 5th installments of Mr. D'Silva's 9/1/2021 grant, these installments vest ratably on 9/1/2025 and 9/1/2026; (ii) 2,217 RSUs which represent the final installment of Mr. D'Silva's 10/3/2022 grant, which installment vests on 10/3/2025; (iii) 3,928 RSUs which represent the 3rd and 4th  installments of Mr. D'Silva's 12/19/2023 grant, which installments vest ratably on 12/19/2025 and 12/19/2026; (iv) 3,472 RSUs which will vest in 3 equal annual installments beginning on 10/1/2025, which is the 1st anniversary of the grant date; and (v) 7,273 RSUs which will vest in three equal annual installments beginning on 12/11/2025, which is the 1st anniversary of the grant date.

(2) The stock option vests in three equal annual installments beginning October 1, 2025, which was the first anniversary of the grant date.

(3) The stock option vests in three equal annual installments beginning September 1, 2022, which was the first anniversary of the grant date.

(4) The stock option vests in three equal annual installments beginning October 3, 2023, which was the first anniversary of the grant date.

(5) The stock option vests in three equal annual installments beginning December 19, 2023, which was the first anniversary of the grant date.

(6) The stock option vests in three equal annual installments beginning December 11, 2024, which was the first anniversary of the grant date.

**Remarks:**
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person

**Signature:** /s/ Marion Odence-Ford, by Power of Attorney  
**Date:** 2025-10-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**